GlassScriptPhysician profile
Andrew M Bernstein
NPI 1669490975
$1,566.37
in general payments reported to CMS, 2019-2025
29 companies · $472 in 2025
The $472 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $371 · 2020: $83.56 · 2021: $161 · 2022: $135 · 2023: $177 · 2024: $166 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.64 |
| Education | $183.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $203.68 | 2021-2025 | |
| Amgen INC. | $158.59 | 2019-2022 | |
| Genentech USA, INC. | $150.35 | 2019-2025 | Lunsumio, Polivy, Tecentriq |
| Merck Sharp & Dohme LLC | $144.02 | 2019-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $123.21 | 2019-2025 | Imfinzi |
| Pfizer INC. | $117.31 | 2024-2025 | |
| Janssen Biotech, INC. | $86.76 | 2021-2025 | Darzalex, Erleada, Talvey |
| E.R. Squibb & Sons, L.L.C. | $52.42 | 2019-2024 | Opdivo |
| Ipsen Biopharmaceuticals, INC | $51.43 | 2020-2025 | Onivyde |
| Foundation Medicine, INC. | $49.86 | 2023 | |
| Astellas Pharma US INC | $41.44 | 2023-2024 | Xtandi |
| Invivyd INC | $33.85 | 2025 | Pemgarda |
| Karyopharm Therapeutics INC. | $30.24 | 2020-2025 | Xpovio |
| Adaptive Biotechnologies Corporation | $28.49 | 2023 | Clonoseq |
| Eisai INC. | $27.78 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25.93 | 2021 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Mirati Therapeutics, INC. | $22.25 | 2023 | Krazati |
| Genmab U.S., INC. | $20.59 | 2024 | Epkinly |
| Exelixis INC. | $20.14 | 2025 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $19.92 | 2023 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $19.44 | 2025 | Libtayo |
| Tersera Therapeutics LLC | $18.14 | 2025 | Xermelo |
| Jazz Pharmaceuticals INC. | $16.67 | 2021 | |
| Geron Corporation | $16.57 | 2025 | Rytelo |
| Array Biopharma INC | $16.21 | 2024 | Braftovi, Tukysa, Mektovi |
| Abbvie INC. | $15.89 | 2025 | |
| Kite Pharma, INC. | $15.88 | 2024 | Yescarta |
| Cti Biopharma Corp. | $15.38 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.